What medication should be given for anxiety in a 14-year-old with trichotillomania?

Treatment Recommendation for Anxiety in a 14-Year-Old with Trichotillomania

For this 14-year-old with trichotillomania and comorbid anxiety, start with an SSRI (selective serotonin reuptake inhibitor) as first-line pharmacologic treatment, with sertraline, fluoxetine, or escitalopram being preferred options. 1

Rationale and Treatment Framework

Why SSRIs Are First-Line

The 2020 AACAP guidelines establish that SSRIs have considerable empirical support as safe and effective treatments for anxiety in children and adolescents ages 6-18 1. This recommendation is based on high-strength evidence showing SSRIs improve:

• Primary anxiety symptoms (clinician, parent, and child report)
• Global functioning
• Treatment response rates
• Disorder remission rates

The Trichotillomania Context

While trichotillomania itself is classified as an obsessive-compulsive related disorder, the anxiety component requires direct treatment. Recent evidence confirms that behavioral interventions (particularly habit reversal training) remain the gold standard for trichotillomania itself, but pharmacotherapy is appropriate when significant comorbid anxiety is present 2. The SSRI will address the anxiety disorder while potentially providing some benefit for the hair-pulling behavior through serotonergic mechanisms.

Specific SSRI Selection and Dosing

Start with one of these three SSRIs:

• Sertraline: Begin at 25 mg daily, increase by 25-50 mg increments every 1-2 weeks as tolerated, target dose 50-200 mg/day
• Fluoxetine: Begin at 5-10 mg daily, increase by 10-20 mg increments every 3-4 weeks (longer half-life), target dose 10-60 mg/day
• Escitalopram: Begin at 5 mg daily, increase by 5 mg increments every 1-2 weeks, target dose 10-20 mg/day

1

Why these three? Sertraline and fluoxetine have the most robust pediatric anxiety data. Escitalopram has the least CYP450 interaction potential, reducing drug-drug interaction concerns 1.

Critical Prescribing Considerations

Start with a subtherapeutic "test" dose because SSRIs can paradoxically cause initial anxiety or agitation 1. This is particularly important in adolescents already experiencing anxiety.

Monitor closely for:

• Suicidal ideation/behavior (FDA black box warning through age 24) - assess at every visit, especially in first 4-8 weeks
• Behavioral activation, agitation, hypomania, or mania
• Gastrointestinal symptoms (nausea, diarrhea, abdominal pain)
• Sleep disturbances (insomnia or somnolence)
• Sexual dysfunction (though less common in this age group)

1

Combination Treatment Consideration

If anxiety is moderate-to-severe, strongly consider adding cognitive-behavioral therapy (CBT) from the outset rather than medication alone. The CAMS study demonstrated that combination treatment (CBT + sertraline) was superior to either monotherapy for:

• Clinician-reported anxiety improvement
• Global functioning
• Treatment response rates
• Disorder remission

1

This is particularly relevant because the patient needs both anxiety management AND behavioral intervention for trichotillomania. The CBT can be adapted to include both anxiety-focused techniques and habit reversal training for hair pulling.

Alternative Pharmacologic Options

If SSRIs fail or are not tolerated, consider an SNRI (serotonin-norepinephrine reuptake inhibitor):

• Duloxetine is the only SNRI with FDA approval for pediatric generalized anxiety disorder (ages 7+)
• Venlafaxine extended-release is another option

1

However, SNRIs have lower strength of evidence compared to SSRIs and carry additional monitoring requirements (blood pressure, heart rate) due to noradrenergic effects 1.

What NOT to Use

Avoid benzodiazepines - Despite historical use, there is insufficient evidence of efficacy in pediatric anxiety disorders, and they carry significant risks including:

• Dependence potential
• Behavioral disinhibition
• Cognitive impairment
• Mood changes

3, 4

Buspirone is not recommended - Randomized controlled trials do not support efficacy in pediatric anxiety 3.

Common Pitfalls to Avoid

1. Discontinuation syndrome: Paroxetine, fluvoxamine, and sertraline have higher risk. If switching medications, taper slowly over 2-4 weeks 1

2. Premature dose escalation: Allow adequate time at each dose (1-2 weeks for shorter half-life SSRIs, 3-4 weeks for fluoxetine) before increasing 1

3. Inadequate trial duration: A full SSRI trial requires 8-12 weeks at therapeutic dose before declaring treatment failure

4. Missing the behavioral component: Medication alone for trichotillomania is insufficient - the patient needs habit reversal training regardless of pharmacotherapy 2

5. Parental oversight: At age 14, ensure parents are actively involved in medication administration and monitoring for adverse effects 1

Monitoring Plan

• Week 1-2: Assess tolerability, emergence of activation/agitation
• Week 4: Assess early response, suicidal ideation
• Week 8: Assess therapeutic response using standardized anxiety rating scales
• Week 12: Determine if full therapeutic benefit achieved; adjust treatment plan accordingly

1